A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

[1]  P. Sonneveld,et al.  Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. , 2011, Blood.

[2]  F. Giles,et al.  Targeting aurora kinases in cancer treatment. , 2011, Current drug targets.

[3]  T. Yamauchi,et al.  A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. , 2011, Leukemia research.

[4]  F. Giles,et al.  The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib , 2011, Journal of cellular and molecular medicine.

[5]  S. Okabe,et al.  Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells , 2010, Annals of Hematology.

[6]  J. Blagg,et al.  Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias , 2010, Leukemia.

[7]  V. Markovtsov,et al.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen , 2009, Journal of Cancer Research and Clinical Oncology.

[8]  H. Kantarjian,et al.  Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia , 2008 .

[9]  D. Bergstrom,et al.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.